• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Mangoceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

    12/19/25 7:30:48 AM ET
    $MGRX
    Misc Health and Biotechnology Services
    Health Care
    Get the next $MGRX alert in real time by email
    false 0001938046 0001938046 2025-12-17 2025-12-17 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

     

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     

    Date of Report (Date of Earliest Event Reported): December 17, 2025

     

    MANGOCEUTICALS, INC.

    (Exact name of registrant as specified in its charter)

     

    Texas   001-41615   87-3841292
    (State or Other Jurisdiction
    of Incorporation)
     

    (Commission

    File Number)

      (IRS Employer
    Identification No.)

     

    17130 N. Dallas Parkway, Suite 240

    Dallas, Texas

      75248
    (Address of Principal Executive Offices)   (Zip Code)

     

    Registrant’s telephone number, including area code: (214) 242-9619

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e 4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Common Stock, par value $0.0001 per share   MGRX  

    The Nasdaq Stock Market LLC

    (Nasdaq Capital Market)

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 1.01 Entry into a Material Definitive Agreement.

     

    On December 17, 2025, Mango DAT, LLC (“Mango DAT”), a wholly owned subsidiary of Mangoceuticals, Inc. (the “Company”) and Cube Operations LLC (“Cube”) entered into a Master Services Agreement (the “Agreement”). Pursuant to the Agreement, Cube is providing Mango DAT access to Cube’s proprietary platform (www.cube.exchange) (including any supporting services thereto), enabling Mango DAT to securely store, manage and administer its holdings of digital assets by using the platform’s MPC Wallet. Cube may at its sole discretion also make additional services and/or software features available to Mango DAT.

     

    Pursuant to the Agreement, Cube will have sole responsibility and authority with respect to the discretionary asset management of Solana tokens that Mango DAT plans to purchase.

     

    In addition, on December 17th, Mango DAT and Cube signed an Order Form (the “Order Form”) whereby Mango DAT agreed to pay Cube a tiered monthly management fee based on assets under management and a two percent (2%) annual management fee based on the initial deposit of Solana tokens and then the 30-day average NAV of the Solana tokens. Mango DAT will pay a minimum monthly management fee of $2,500.

     

    Pursuant to the Order Form, Mango DAT has the right to buy other assets that would be managed by Cube pursuant to the Agreement and the Order Form.

     

    The foregoing description of the Agreement and the Order Form is not complete and is qualified in its entirety by reference to the full text of the Agreement and the Order Form, copies of which are filed herewith as Exhibits 10.1 and 10.2 to this Current Report on Form 8-K and are incorporated herein by reference.

     

    Item 8.01 Other Events.

     

    On December 19, 2025, the Company issued a press release announcing Mango DAT’s entrance into the Agreement with Cube. A copy of the press release is filed as Exhibit 99.1 to this Form 8-K and is incorporated herein by reference.

     

    Item 9.01 Financial Statements and Exhibits.

     

    (d) Exhibits.

     

    Exhibit

    Number

      Description
    10.1   Master Services Agreement by and between Mango DAT, LLC and Cube Operations LLC, dated as of December 17, 2025
    10.2   Order Form by and between Mango DAT, LLC and Cube Operations LLC, dated as of December 17, 2025
    99.1   Press release dated December 19, 2025 announcing the Master Services Agreement
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      MANGOCEUTICALS, INC.
                                                   
    Date: December 19, 2025 By: /s/ Jacob D. Cohen
        Jacob D. Cohen
        Chief Executive Officer

     

     

    Get the next $MGRX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MGRX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $MGRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Mangoceuticals, Inc. Announces Closing of $2.5 Million Registered Direct and Private Placements

    DALLAS, TX, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX) (the "Company"), a company focused on developing, marketing, and selling a variety of health and wellness products via a secure telemedicine platform under the brands MangoRx and PeachesRx, today announced the closing of its previously announced registered direct offering and concurrent private placement with institutional investors. The Company issued shares of Common Stock and pre-funded warrants in a registered direct offering. In a concurrent private placement, the Company also issued to the same investors investor warrants. Aggregate gross proceeds to the Company from both transactions were approximately

    12/19/25 10:38:00 AM ET
    $MGRX
    Misc Health and Biotechnology Services
    Health Care

    Mangoceuticals, Inc. Announces Partnership with The Cube Group to Launch Up To $100 Million Solana-Focused Digital Asset Treasury (DAT) Strategy

    MULTI-DAT Framework Drives Diversified Crypto Expansion and Volatility Hedging DALLAS, TX, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX) (the "Company"), a company focused on developing, marketing, and selling a variety of health and wellness products via a secure telemedicine platform under the brands MangoRx and PeachesRx, today announced an up to $100 million Solana-focused digital asset treasury (DAT) strategy in partnership with Cube Group, through its newly formed subsidiary, Mango DAT, LLC. This initiative positions Mangoceuticals at the forefront of institutional adoption in the Solana ecosystem, leveraging high-yield opportunities to drive sustainable, non

    12/19/25 7:30:00 AM ET
    $MGRX
    Misc Health and Biotechnology Services
    Health Care

    Mangoceuticals, Inc. Announces $2.5 Million Registered Direct and Private Placements Priced at the Market Under Nasdaq Rules

    DALLAS, TX, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX) (the "Company"), a company focused on developing, marketing, and selling a variety of health and wellness products via a secure telemedicine platform under the brands MangoRx and PeachesRx, today announced that it has entered into definitive agreements with institutional investors for the purchase and sale of shares of Common Stock and pre-funded warrants in a registered direct offering. In a concurrent private placement, the Company also agreed to sell to the same investors investor warrants. Aggregate gross proceeds to the Company from both transactions are expected to be approximately $2.5 million. The enti

    12/18/25 8:30:00 AM ET
    $MGRX
    Misc Health and Biotechnology Services
    Health Care

    $MGRX
    SEC Filings

    View All

    Mangoceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

    8-K - MANGOCEUTICALS, INC. (0001938046) (Filer)

    12/19/25 9:28:40 AM ET
    $MGRX
    Misc Health and Biotechnology Services
    Health Care

    SEC Form 424B5 filed by Mangoceuticals Inc.

    424B5 - MANGOCEUTICALS, INC. (0001938046) (Filer)

    12/19/25 9:13:58 AM ET
    $MGRX
    Misc Health and Biotechnology Services
    Health Care

    Mangoceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

    8-K - MANGOCEUTICALS, INC. (0001938046) (Filer)

    12/19/25 7:30:48 AM ET
    $MGRX
    Misc Health and Biotechnology Services
    Health Care

    $MGRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CFO Johnston Eugene M sold $3,884 worth of shares (3,333 units at $1.17), decreasing direct ownership by 3% to 120,000 units (SEC Form 4)

    4 - MANGOCEUTICALS, INC. (0001938046) (Issuer)

    12/17/25 5:00:28 PM ET
    $MGRX
    Misc Health and Biotechnology Services
    Health Care

    CFO Johnston Eugene M sold $5,975 worth of shares (5,000 units at $1.20), decreasing direct ownership by 4% to 123,333 units (SEC Form 4)

    4 - MANGOCEUTICALS, INC. (0001938046) (Issuer)

    12/11/25 4:05:11 PM ET
    $MGRX
    Misc Health and Biotechnology Services
    Health Care

    CFO Johnston Eugene M sold $11,280 worth of shares (10,000 units at $1.13), decreasing direct ownership by 7% to 128,333 units (SEC Form 4)

    4 - MANGOCEUTICALS, INC. (0001938046) (Issuer)

    12/9/25 5:16:13 PM ET
    $MGRX
    Misc Health and Biotechnology Services
    Health Care

    $MGRX
    Financials

    Live finance-specific insights

    View All

    Mangoceuticals, Inc. Completes Acquisition of Mushroom-Based Wellness and Innovations Patent

    Dallas, TX, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX) ("MangoRx" or the "Company"), a company focused on developing, marketing, and selling men's health and wellness products via a secure telemedicine platform, today announced the acquisition of patent number WO 2023/086647 PCT/US2022/049857, for mushroom-derived compositions and methods of treatment. This new addition to MangoRx's intellectual property portfolio highlights the Company's commitment to innovative solutions that support holistic health and wellness. The acquired patent encompasses nutraceutical compositions derived from functional mushrooms, including well-known varieties such as Cordyceps sinensi

    12/19/24 5:33:00 PM ET
    $MGRX
    Misc Health and Biotechnology Services
    Health Care

    MangoRx Reports 1,685% Increase in Shareholders' Equity From December 31, 2023, to $13.8MM, and 56% Increase in Year-Over-Year Revenue for First Half of 2024

    Dallas, Texas, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX) ("MangoRx" or the "Company"), a company focused on developing, marketing, and selling a variety of men's health and wellness products in the area of erectile dysfunction (ED), hair growth, weight loss, and hormone replacement therapies, today announced its financial results for the three and six months ending June 30, 2024, showing a significant growth in both shareholder's equity and gross revenues. During the six months ending June 30, 2024, MangoRx's shareholder equity increased to $13,829,445, compared to $774,754 as of December 31, 2023, reflecting an increase of 1,685%, or $13,054,691. A substantial

    8/15/24 9:25:00 AM ET
    $MGRX
    Misc Health and Biotechnology Services
    Health Care

    $MGRX
    Leadership Updates

    Live Leadership Updates

    View All

    Mangoceuticals Announces Strategic Entry into High Growth Pouch Industry Through Acquisition of Smokeless Technology IP and Appointment of Tim Corkum Ex Philip Morris Executive to Lead High Growth Pouch Division

    DALLAS, TX, April 25, 2025 (GLOBE NEWSWIRE) -- Mangoceuticals Inc. (NASDAQ:MGRX) ("Mangoceuticals" or "MGRX"), a company focused on developing, marketing, and selling a variety of health and wellness products via a secure telemedicine platform under the brands MangoRx and PeachesRx, is pleased to announce that it has entered into an Intellectual Property Purchase Agreement to acquire all intellectual property, product formulations, know-how, distribution, supplier relationships and related assets of Smokeless Technology Corp. ("Smokeless Tech"), a Canadian-based pouch innovation company specializing in stimulant and functional pouches. This acquisition marks a strategic expansion into the

    4/25/25 9:00:00 AM ET
    $MGRX
    Misc Health and Biotechnology Services
    Health Care

    $MGRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Mangoceuticals Inc.

    SC 13D/A - MANGOCEUTICALS, INC. (0001938046) (Subject)

    8/27/24 7:45:22 PM ET
    $MGRX
    Misc Health and Biotechnology Services
    Health Care

    SEC Form SC 13D/A filed by Mangoceuticals Inc. (Amendment)

    SC 13D/A - MANGOCEUTICALS, INC. (0001938046) (Subject)

    6/5/24 5:15:19 PM ET
    $MGRX
    Misc Health and Biotechnology Services
    Health Care